NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

S. M. Ansell; P. J. Bröckelmann; G. von Keudell; H. J. Lee; A. Santoro; P. L. Zinzani; G. P. Collins; J. B. Cohen; J. P. De Boer; J. Kuruvilla; K. J. Savage; M. Trneny; M. Provencio; U. Jaeger; W. Willenbacher; R. Swanink; M. Sacchi; M. A. Shipp; A. Engert; P. Armand

Journal ArticleOPEN ACCESS

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Ansell S
Bröckelmann P
von Keudell G
et al.

Hematological Oncology (2021) 39(S2)

DOI: 10.1002/hon.74_2879

N/ACitations

7Readers

Abstract

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Cite

CITATION STYLE

APA

Ansell, S. M., Bröckelmann, P. J., von Keudell, G., Lee, H. J., Santoro, A., Zinzani, P. L., … Armand, P. (2021). NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. Hematological Oncology, 39(S2). https://doi.org/10.1002/hon.74_2879

NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY

Abstract

Cite

Register to see more suggestions